Codexis, a leading provider of enzymatic solutions for efficient and scalable manufacturing of complex oligonucleotide therapeutics, shared new advances in RNA therapeutic manufacturing at TIDES USA ...

Researchers at the International Institute of Molecular and Cell Biology in Warsaw (IIMCB), led by Prof. Gracjan Michlewski, ...

The global oligonucleotide CDMO market is emerging as one of the fastest-growing segments within the pharmaceutical ...

The field of RNA biology has become increasingly significant in understanding the molecular mechanisms that underpin aging. Recent evidence suggests that ...

Researchers discovered that polio and common cold viruses appear to rely on the same vulnerable mechanism to survive and ...

Codexis outlined ongoing commercial discussions supported by a "very, very healthy" sales funnel spanning large pharma, ...

Hongene Biotech shows advanced oligonucleotide CDMO capabilities via support of SiranBio’s dual-target siRNA programme: Singapore Saturday, May 9, 2026, 16:00 Hrs [IST] Hongene ...

Agilent Technologies (NYSE:A) has licensed its long RNA purification technology to Cirena for genome editing applications.

When researchers first observed the presence of circular RNAs in the 1970s, they were an inexplicable biological oddity — and they remained so for many years afterward. The field of RNA biology was in ...

Codexis (NASDAQ:CDXS) reported first-quarter 2026 revenue of $15.2 million, up from $7.5 million a year earlier, as the company highlighted continued progress commercializing its ECO Synthesis ...

Zhejiang Hengkang Pharmaceutical Co., Ltd. continues to strengthen its position as a leading manufacturer within the global active pharmaceutical ingredient industry, attracting growing attention for ...